NYSE - Nasdaq Real Time Price USD

Arcus Biosciences, Inc. (RCUS)

8.11

+0.02

+(0.25%)

At close: April 23 at 4:00:02 PM EDT

8.28

+0.17

+(2.10%)

After hours: April 23 at 6:54:50 PM EDT

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

HAYWARD, Calif., April 23, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that data from the ARC-20 study will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3, 2025.

Business Wire 6 hours ago

RCUS
+0.25%
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

HAYWARD, Calif., April 22, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended March 31st, 2025.

Business Wire yesterday

RCUS
+0.25%
Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., April 09, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 16,960 shares of the Company’s common stock at an exercise price per share of $7.04, which was the closing price on April 8, 2025, and rest

Business Wire 14 days ago

RCUS
+0.25%
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures

Key Insights Institutions' substantial holdings in Arcus Biosciences implies that they have significant influence over...

Simply Wall St. 25 days ago

RCUS
+0.25%
Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Arcus Biosciences, Inc. (NYSE:RCUS) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical […]

Insider Monkey last month

RCUS
+0.25%
Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are going to take a look at where Arcus Biosciences, Inc. (NYSE:RCUS) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, the stock market has […]

Insider Monkey last month

RCUS
+0.25%
Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares

Potential Arcus Biosciences, Inc. ( NYSE:RCUS ) shareholders may wish to note that the Co-Founder, Terry Rosen...

Simply Wall St. last month

RCUS
+0.25%
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

There's been a notable change in appetite for Arcus Biosciences, Inc. ( NYSE:RCUS ) shares in the week since its annual...

Simply Wall St. last month

RCUS
+0.25%
Arcus Biosciences to Participate in Two Upcoming Investor Conferences

HAYWARD, Calif., February 26, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March:

Business Wire last month

RCUS
+0.25%
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 11.97% and 9.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

RCUS
+0.25%
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

HAYWARD, Calif., February 25, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers.

Business Wire last month

RCUS
+0.25%
These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts

One thing we could say about the analysts on Arcus Biosciences, Inc. ( NYSE:RCUS ) - they aren't optimistic, having...

Simply Wall St. 2 months ago

RCUS
+0.25%
Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. “ARC-20 is a Phase 1/1b dose-escalation and expansion study. New data include mPFS and ORR for the 50mg BID cohort, and ORR for the 50mg once-daily and 100mg QD cohorts, all of which evaluated casdatifan in patients with metas

TipRanks 2 months ago

RCUS
+0.25%
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

HAYWARD, Calif., February 18, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that Gilead’s time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has announced the pricing of a $150 million common stock offering, which is subject to customary closing conditions and includes participation from new and existin

Business Wire 2 months ago

RCUS
+0.25%
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

HAYWARD, Calif., February 18, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of $11.00 per share, for total gross proceeds of approximately $150 million, before deducting underwriting discounts and commissions and offering expenses payabl

Business Wire 2 months ago

RCUS
+0.25%
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

HAYWARD, Calif., February 15, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium.

Business Wire 2 months ago

RCUS
+0.25%
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

HAYWARD, Calif., February 10, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that data from the ARC-20 study will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium taking place February 13 – 15, 2025, in San Francisco, CA.

Business Wire 2 months ago

RCUS
+0.25%
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

HAYWARD, Calif., January 21, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus’s responsi

Business Wire 2 months ago

RCUS
+0.25%
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 3 months ago

MRNA

RCUS
+0.25%
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

Simply Wall St. 4 months ago

RCUS
+0.25%

Performance Overview

Return	RCUS	S&P 500 (^GSPC)
YTD	-45.53%	-8.60%
1-Year	-47.68%	+6.02%
3-Year	-70.40%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures

Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month

Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently

Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts

Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?

Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week

Performance Overview